Mucosal innate immune factors in secretions from high-risk individuals immunized with a bivalent gp120 vaccine

AIDS Research and Human Retroviruses

Volumn 23, Issue 5, 2007, Pages 748-754

  Cummins Jr , James E ^a,f   Denniston, Maxine ^a   Mayer, Kenneth H ^b   Pickard, Robert ^b   Novak, Richard M ^c   Graham, Parrie ^c   Gurwith, Marc ^d   Orelind, Karen ^d   Ackers, Marta L ^a   Dezzutti, Charlene S ^a,e  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Fenway Community Health   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d VaxGen Inc   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GENITAL SYSTEM; GINGIVA; HIGH RISK POPULATION; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; MUCOSA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SERUM; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; VACCINATION;

ADOLESCENT; ADULT; AIDS VACCINES; BODILY SECRETIONS; CALGRANULIN B; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, MUCOSAL; IMMUNITY, NATURAL; LACTOFERRIN; MALE; MIDDLE AGED; RISK FACTORS; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; VACCINES, SYNTHETIC;

EID: 34249912114     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.0233     Document Type: Article

References (16)

1. Hashemi FB, Mollenhauer J, Madsen LD, et al.: Myeloid-related protein (MRP)-8 from cervico-vaginal secretions activates HIV replication. AIDS 2001:15:441-449.
2. Ryckman C. Robichaud GA, Roy J. Cantin R. Tremblay MJ, and Tessier PA: HIV-1 transcription and virus production are both accentuated by the proinflammatory myeloid-related proteins in human CD4+ T lymphocytes. J Immunol 2002;169:3307-3313.
3. Berkhout B. van Wamel JL, Beljaars L, Meijer DK, Visser S, and Floris R: Characterization of the anti-HIV effects of native lactoferrin and other milk proteins and protein-derived peptides. Antiviral Res 2002;55:341-355.
4. Groot F, Geijtenbeek TB. Sanders RW, et al.: Lactoferrin prevents dendritic cell-mediated human immunodeficiency virus type 1 transmission by blocking the DC-SIGN-gp120 interaction. J Virol 2005:79:3009-3015.
5. Ma G, Greenwell-Wild T. Lei K. et al.: Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med 2004;200:1337-1346.
6. Shine NR, Wang SC, Konopka K. Burks EA. Duzgunes N. and Whitman CP: Secretory leukocyte protease inhibitor: Inhibition of human immunodeficiency virus-1 infection of monocytic THP-1 cells by a newly cloned protein. Bioorg Chem 2002;30:249-263.
7. Cummins JE, Christensen L. Lennox, JL, et al.: Mucosal innate immune factors in the female genital tract are associated with vaginal HIV-1 shedding independent of plasma viral load. AIDS Res Hum Retroviruses 2006;22:788-795.
8. Flynn NM, Forthal DN, Harro CD, Judson FN. Mayer KH. and Para MF: Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005;191:654-665.
9. Harro CD, Judson FN, Gorse GJ, et al.: Recruitment and baseline epidemiologic profile of participants in the first phase 3 HIV vaccine efficacy trial. J Acquir Immune Defic Syndr 2004;37:1385-1392.
10. Joint United Nations Program on HIV/AIDS and World Health Organization: AIDS Epidemic Update. UNAIDS, Geneva, 2004.
11. Basset C, Holton J, O'Mahony R, and Roitt 1: Innate immunity and pathogen-host interaction. Vaccine 2O03;21(Suppl. 2):S12-S23.
12. Lehner T and Anton PA: Mucosal immunity and vaccination against HIV. AIDS 2002;16(Suppl. 4):S125-S132.
13. Kozlowski PA, Cu-Uvin S, Neutra MR, and Flanigan TP: Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun 1997;65:1387-1394.
14. Levay PF and Viljoen M: Lactoferrin: A general review. Haematologica 1995;80:252-267.
15. Valore EV, Park CH, Igreti SL. and Ganz T: Antimicrobial components of vaginal fluid. Am J Obstet Gynecol 2002:187:561-568.
16. Bartholow. BN, Buchbinder, S, Celum, C. et al.: HIV sexual risk behavior over 36 months of follow-up in the world's first HIV vaccine efficacy trial. J Acquir Immune Defic Syndr 2005:39:90-101.